Drug Approval | October 16, 2024
Shilpa Medicare’s CDMO customer gets fast-track designation for its investigational drug candidate
GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally
GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally
He will join in place of Anil Arora, current President- Formulations Operations who will be superannuating in November, 2024
The partnership marks a pivotal step towards developing new therapies for combating Sickle Cell Disease
Paliperidone extended-release tablets will be produced at the Group’s manufacturing site at SEZ, Ahmedabad
Aims to achieve CDMO sales of US$ 400 million by 2028
We now rank 3rd in pharmaceutical production by volume and 14th by value
To set a new standard in oncology, offering highly targeted radiation therapy that improves treatment precision, and accelerates recovery for cancer patients
Mylan and Novo Nordisk reach settlement of US patent litigation related to Ozempic
Poor oral health (periodontal disease) impacts nearly 51% of Indians
Emcure will play a crucial role in ensuring the availability of high-quality, low-cost versions of lenacapavir in 120 countries
Subscribe To Our Newsletter & Stay Updated
